New hope for multiple myeloma: phase 3 trial launches

NCT ID NCT07623798

Not yet recruiting Disease control Sponsor: Innovent Biologics (Suzhou) Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase 3 trial tests a new drug called IBI3003 against standard treatments for people with multiple myeloma that has returned or is not responding to therapy. About 255 participants will be randomly assigned to receive either IBI3003 or a standard treatment chosen by their doctor. The main goal is to see if IBI3003 helps people live longer without the cancer getting worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IBI3003 (a drug being tested against standard treatments like pomalidomide, bortezomib, and daratumumab)
What this could lead to: If it works, this could offer a new treatment option for people with multiple myeloma that has come back or stopped responding to therapy.
What could go wrong: This is an early-stage Phase 3 trial, so results are not yet known. The new drug may not work better than existing treatments and could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Recurrence refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

ZhongShan Hospital FuDan University

Shanghai, Shanghai Municipality, 132101, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.